Blog

Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy

Paolo Tarantino and Sara Tolaney

Nov 13, 2024, 09:11

Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy

Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared a recent article by A.S. Raghavendra on X:

“Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status.

HER2-low eTNBC showed no pCR or survival benefit over HER2 IHC score 0.
RFS did not significantly differ between HER2 IHC categories after NAT.
HER2-low tumors had higher nodal positivity (55%) than HER2 IHC score 0 (46.6%); P = 0.011.
Post-treatment HER2 IHC status changed in 31.1% of HER2 IHC score 0 and 34.8% of HER2-low cases.
HER2 IHC status discordance underscores quantification and heterogeneity challenges.”

Title: Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status

Authors: A.S. Raghavendra, D.B. Zakon, Q. Jin, A. Strahan, M. Grimm, M.E. Hughes, M. Cherian, J. Vincuilla, T. Parker, Paolo Tarantino, E.A. Mittendorf, T.A. King, V. Valero, D. Tripathy, S.M. Tolaney, N. Tayob, N.U. Lin, D.G. Stover, C.H. Barcenas and A.C. Garrido-Castro.

breast cancer

For more updates, follow OncoDaily.

A. Strahan A.C. Garrido-Castro A.S. Raghavendra Breast Cancer C.H. Barcenas cancer chemotherapy D.B. Zakon D.G. Stover Elisabetta Bonzano M. Cherian M. Grimm M.E. Hughes N.U. Lin OncoDaily Oncology Q. Jin TNBC

Melanie Griffith and Skin Cancer: How She Went Against, How She Survived, and More

New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression

Gemma Peters: Heading into 2025 with hope

Carlos Rodriguez-Galindo: The Man Who Will Cure the World

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Special Coverage